GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (STU:XE7C) » Definitions » Pretax Margin %

Cardiff Oncology (STU:XE7C) Pretax Margin % : -4,873.02% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cardiff Oncology Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Cardiff Oncology's Pre-Tax Income for the three months ended in Mar. 2024 was €-9.21 Mil. Cardiff Oncology's Revenue for the three months ended in Mar. 2024 was €0.19 Mil. Therefore, Cardiff Oncology's pretax margin for the quarter that ended in Mar. 2024 was -4,873.02%.

The historical rank and industry rank for Cardiff Oncology's Pretax Margin % or its related term are showing as below:

STU:XE7C' s Pretax Margin % Range Over the Past 10 Years
Min: -10289.76   Med: -7290.05   Max: -4354.76
Current: -6594.92


STU:XE7C's Pretax Margin % is ranked worse than
88.28% of 1032 companies
in the Biotechnology industry
Industry Median: -167.31 vs STU:XE7C: -6594.92

Cardiff Oncology Pretax Margin % Historical Data

The historical data trend for Cardiff Oncology's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Pretax Margin % Chart

Cardiff Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6,684.62 -5,272.43 -7,873.58 -10,037.64 -8,501.34

Cardiff Oncology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13,438.46 -10,291.00 -6,907.58 -5,987.41 -4,873.02

Competitive Comparison of Cardiff Oncology's Pretax Margin %

For the Biotechnology subindustry, Cardiff Oncology's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiff Oncology's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Pretax Margin % falls into.



Cardiff Oncology Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Cardiff Oncology's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-38.001/0.447
=-8,501.34 %

Cardiff Oncology's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-9.21/0.189
=-4,873.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardiff Oncology  (STU:XE7C) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Cardiff Oncology Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiff Oncology (STU:XE7C) Business Description

Traded in Other Exchanges
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

Cardiff Oncology (STU:XE7C) Headlines

No Headlines